Contract development and manufacturing organisation (CDMO), Juniper Pharma Services, has revealed its expansion into its UK-based drug development and clinical trial manufacturing facilities.
Nottingham
The company will extend its facilities with four additional process development laboratories at its site in Nottingham. This expansion will improve the output and efficiency of its development and clinical manufacturing operations.
“We are always exploring opportunities to extend our service offerings to meet the evolving requirements of our market and clients,” commented Nikin Patel, president at Juniper Pharma Services. “This facility expansion, which has significantly increased Juniper Pharma Services’ capacity, is the latest effort in this endeavour.”
The new lab space is set to be operational by the summer this year (2018) and will enable the company to work with an ever-growing client base to transform poorly soluble and difficult to formulate molecules into successful products. Additionally, it will ensure that the processing and formulation work of the company is scalable, enabling the efficient manufacture of stability and clinical batches.
This growth shows how the company has progressed within the field of drug development and its increasing commitment to solve formulation challenges.